Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3101
Employers Holdings
EIG
$871M
| $1.5M | ﹤0.01% |
34,850
-45
| -0.1% | -$1.83K |
|
3102
GigaCloud Technology
GCT
$1.9B
| $1.5M | ﹤0.01% |
38,196
-6,533
| -15% | -$216K |
|
3103
Orange County Bancorp
OBT
$524M
| $1.5M | ﹤0.01% |
52,551
+2,721
| +5% | +$71.5K |
|
|
CWBC
3104
Community West Bancshares
CWBC
$706M
| $1.5M | ﹤0.01% |
66,643
+8,698
| +15% | +$191K |
|
3105
Fulcrum Therapeutics
FULC
$283M
| $1.5M | ﹤0.01% |
132,541
+42,925
| +48% | +$437K |
|
3106
PUT
Blackrock
BLK
$183B
| $1.5M | ﹤0.01% |
1,400
-700
| -33% | -$765K |
|
3107
Erasca
ERAS
$6.25B
| $1.5M | ﹤0.01% |
402,796
+134,544
| +50% | +$378K |
|
3108
Clover Health Investments
CLOV
$2.38B
| $1.5M | ﹤0.01% |
637,279
+59,327
| +10% | +$162K |
|
3109
CALL
SiriusXM
SIRI
$9.43B
| $1.5M | ﹤0.01% |
74,840
| – | – |
|
3110
Vestis
VSTS
$1.79B
| $1.49M | ﹤0.01% |
223,968
-8,430
| -4% | -$49.1K |
|
|
MFA
3111
MFA Financial
MFA
$931M
| $1.49M | ﹤0.01% |
160,407
+15,390
| +11% | +$143K |
|
3112
iShares US Treasury Bond ETF
GOVT
$43.8B
| $1.49M | ﹤0.01% |
64,720
-340,131
| -84% | -$7.87M |
|
3113
Shutterstock
SSTK
$217M
| $1.49M | ﹤0.01% |
77,914
+16,568
| +27% | +$354K |
|
|
NESR
3114
National Energy Services Reunited Corp
NESR
$3.62B
| $1.49M | ﹤0.01% |
95,001
+9,126
| +11% | +$120K |
|
3115
CALL
Toll Brothers
TOL
$14B
| $1.49M | ﹤0.01% |
11,000
| – | – |
|
3116
Pennant Group
PNTG
$1.35B
| $1.49M | ﹤0.01% |
52,832
+3,908
| +8% | +$104K |
|
3117
Akebia Therapeutics
AKBA
$241M
| $1.49M | ﹤0.01% |
923,507
-256,726
| -22% | -$538K |
|
3118
Tiptree Inc
TIPT
$677M
| $1.49M | ﹤0.01% |
81,306
+14,920
| +22% | +$272K |
|
3119
SFL Corp
SFL
$1.61B
| $1.48M | ﹤0.01% |
189,218
+18,398
| +11% | +$141K |
|
3120
Cenovus Energy
CVE
$56.4B
| $1.48M | ﹤0.01% |
87,232
-315,672
| -78% | -$5.48M |
|
3121
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$34.7B
| $1.47M | ﹤0.01% |
+9,500
| New | +$1.46M |
|
|
3122
PUT
State Street Industrial Select Sector SPDR ETF
XLI
$34.7B
| $1.47M | ﹤0.01% |
9,500
-35,500
| -79% | -$5.46M |
|
3123
Midland States Bancorp
MSBI
$698M
| $1.47M | ﹤0.01% |
69,453
+8,536
| +14% | +$151K |
|
|
ZEUS
3124
DELISTED
Olympic Steel
ZEUS
| $1.47M | ﹤0.01% |
34,274
-83,496
| -71% | -$2.98M |
|
3125
Metropolitan Bank Holding Corp
MCB
$1.17B
| $1.47M | ﹤0.01% |
19,201
+5,204
| +37% | +$385K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.